The stock of BioAtla Inc (NASDAQ: BCAB) has decreased by -6.29% when compared to last closing price of $0.4.Despite this, the company has seen a loss of -0.64% in its stock price over the last five trading days. globenewswire.com reported 2025-07-03 that Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented first-in-human data in a poster titled “Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma” at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress being held in Barcelona, Spain from July 2–5, 2025. In the ongoing Phase 1 dose-escalation clinical trial, as of June 20, 2025, 39 patients with heavily pretreated metastatic adenocarcinoma were dosed in cohorts ranging from 0.0026 mg to 0.6 mg BA3182 QW, with either 0, 1, or 2 priming dose(s) delivered four to seven days prior to treatment dosing.
Is It Worth Investing in BioAtla Inc (NASDAQ: BCAB) Right Now?
The 36-month beta value for BCAB is at 0.90. Analysts have varying views on the stock, with 2 analysts rating it as a “buy”, 1 rating it as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for BCAB is 44.43M, and currently, shorts hold a 9.28% of that float. The average trading volume for BCAB on July 03, 2025 was 520.09K shares.
BCAB’s Market Performance
BCAB’s stock has seen a -0.64% decrease for the week, with a -28.71% drop in the past month and a 9.78% gain in the past quarter. The volatility ratio for the week is 8.26%, and the volatility levels for the past 30 days are at 11.60% for BioAtla Inc The simple moving average for the past 20 days is -10.69% for BCAB’s stock, with a -58.09% simple moving average for the past 200 days.
Analysts’ Opinion of BCAB
JMP Securities, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $17. The rating they have provided for BCAB stocks is “Mkt Outperform” according to the report published on September 15th, 2022.
H.C. Wainwright gave a rating of “Buy” to BCAB, setting the target price at $25 in the report published on March 21st of the previous year.
BCAB Trading at -13.78% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.24% of loss for the given period.
Volatility was left at 11.60%, however, over the last 30 days, the volatility rate increased by 8.26%, as shares sank -19.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.83% upper at present.
During the last 5 trading sessions, BCAB rose by +1.31%, which changed the moving average for the period of 200-days by -79.01% in comparison to the 20-day moving average, which settled at $0.4176. In addition, BioAtla Inc saw -72.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of BioAtla Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -6.1% for the present operating margin
- 0.98% for the gross margin
The net margin for BioAtla Inc stands at -5.63%. The total capital return value is set at -3.01%. Equity return is now at value -246.21%, with -97.07% for asset returns.
Based on BioAtla Inc (BCAB), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -103.6.
Currently, EBITDA for the company is -73.94 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of -0.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In conclusion, BioAtla Inc (BCAB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
